Randomized phase III trial of cisplatin (NSC-119875) and irinotecan (NSC-616348) versus cisplatin and etoposide (NSC-141540) in patients with extensive stage small cell lung cancer (E-SCLC).

Trial Profile

Randomized phase III trial of cisplatin (NSC-119875) and irinotecan (NSC-616348) versus cisplatin and etoposide (NSC-141540) in patients with extensive stage small cell lung cancer (E-SCLC).

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2013

At a glance

  • Drugs Cisplatin (Primary) ; Etoposide; Irinotecan
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Apr 2009 Results have been published in the Journal of Clinical Oncology.
    • 06 Apr 2009 Primary endpoint 'Survival' has not been met.
    • 26 Jun 2008 Results reported at ASCO 2008 (1112883)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top